Capricor Therapeutics Inc Cash Flow Conversion Efficiency
Capricor Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has a cash flow conversion efficiency ratio of -0.105x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.25 Million) by net assets ($278.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Capricor Therapeutics Inc (1999–2025)
Cash flow conversion efficiency of Capricor Therapeutics Inc from 1999 to 2025. This chart illustrates how Capricor Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Capricor Therapeutics Inc stock price today for real-time trading data and today's change.
Capricor Therapeutics Inc Cash Flow Conversion Ratio Explained
Capricor Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Capricor Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Capricor Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market value of Capricor Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
San Shing Fastech Corp
TW:5007
|
0.016x |
|
EagleRock Land, LLC
NYSE:EROK
|
0.000x |
|
Pekat Group Bhd
KLSE:0233
|
0.033x |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
0.029x |
|
MAS Financial Services Limited
NSE:MASFIN
|
-0.330x |
|
Shanghai Golden Bridge
SHG:603918
|
0.043x |
|
Chorus Aviation Inc
TO:CHR
|
0.127x |
|
Temple & Webster Group Ltd
AU:TPW
|
0.227x |
Annual Cash Flow Conversion Efficiency for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Capricor Therapeutics Inc from 1999 to 2025. Review Capricor Therapeutics Inc (CAPR) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.79 Million | $-69.81 Million | -0.228x | +16.97% |
| 2024-12-31 | $145.46 Million | $-40.00 Million | -0.275x | +75.72% |
| 2023-12-31 | $22.60 Million | $-25.60 Million | -1.133x | -371.49% |
| 2022-12-31 | $11.79 Million | $4.92 Million | 0.417x | +177.85% |
| 2021-12-31 | $31.37 Million | $-16.81 Million | -0.536x | -50.29% |
| 2020-12-31 | $28.20 Million | $-10.05 Million | -0.357x | +64.25% |
| 2019-12-31 | $6.84 Million | $-6.82 Million | -0.997x | +66.79% |
| 2018-12-31 | $4.62 Million | $-13.86 Million | -3.003x | -136.94% |
| 2017-12-31 | $11.23 Million | $-14.23 Million | -1.268x | -132.11% |
| 2016-12-31 | $-4.00 Million | $-15.80 Million | 3.947x | -62.35% |
| 2015-12-31 | $-1.03 Million | $-10.82 Million | 10.484x | +6934.47% |
| 2014-12-31 | $-6.25 Million | $958.56K | -0.153x | -101.34% |
| 2013-12-31 | $-534.88K | $-6.14 Million | 11.487x | +2671.04% |
| 2012-12-31 | $4.89 Million | $-2.19 Million | -0.447x | +92.02% |
| 2011-12-31 | $830.72K | $-4.65 Million | -5.597x | -236.57% |
| 2010-12-31 | $2.60 Million | $-4.32 Million | -1.663x | +14.43% |
| 2009-12-31 | $2.98 Million | $-5.80 Million | -1.943x | +6.78% |
| 2008-12-31 | $5.10 Million | $-10.64 Million | -2.085x | -489.82% |
| 2007-12-31 | $15.20 Million | $-5.37 Million | -0.353x | -183.02% |
| 2006-12-31 | $-130.58K | $-55.60K | 0.426x | +85.78% |
| 2005-12-31 | $-77.62K | $-17.79K | 0.229x | -13.00% |
| 2004-12-31 | $-58.76K | $-15.48K | 0.263x | -48.52% |
| 2003-12-31 | $-40.69K | $-20.82K | 0.512x | -12.35% |
| 2002-12-31 | $-24.53K | $-14.32K | 0.584x | -59.91% |
| 2001-12-31 | $-8.94K | $-13.02K | 1.456x | +152.13% |
| 2000-12-31 | $13.36K | $-37.32K | -2.793x | -291.50% |
| 1999-12-31 | $-617.00 | $-900.00 | 1.459x | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more